Antigen-specific proliferative response in bulk culture and frequency of antigen-specific PTLp in LDAs
. | . | 3-5 mo after CBT . | . | . | . | 12-15 mo after CBT . | . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | HCMV reactive . | HCMV . | . | CA . | . | HCMV . | . | CA . | . | ||||||
Patient no. . | . | Bulk PR . | LDA F . | Bulk PR . | LDA F . | Bulk PR . | LDA F . | Bulk PR . | LDA F . | ||||||
CBT-sib | |||||||||||||||
1 | Yes | + | ND | − | ND | + | ND | + | ND | ||||||
2 | Yes | + | ND | + | ND | + | ND | + | ND | ||||||
3 | No | ND | ND | − | ND | ND | ND | − | ND | ||||||
4 | No | ND | ND | + | ND | ND | ND | + | ND | ||||||
5 | No | ND | ND | + | ND | ND | ND | + | ND | ||||||
6 | No | + | 40 | + | 76 | + | 77 | + | 76 | ||||||
7 | No | + | 80 | − | 15 | + | 160 | + | 210 | ||||||
8 | No | + | 125 | + | 111 | + | 313 | + | 365 | ||||||
9 | No | + | 325 | − | 11 | + | 350 | + | 380 | ||||||
10 | No | + | 550 | − | 12 | + | 520 | + | 90 | ||||||
11 | No | − | 15 | + | 48 | − | 12 | − | 16 | ||||||
CBT-ud | |||||||||||||||
12 | No | − | ND | − | ND | + | ND | − | ND | ||||||
13 | No | ND | ND | + | ND | ND | ND | + | ND | ||||||
14 | Yes | + | 62 | − | 19 | + | 66 | + | 125 | ||||||
15 | No | − | − | − | − | − | − | − | − | ||||||
16 | Yes | − | 12 | − | 43 | − | 12 | − | 6 | ||||||
Control ranges | NA | + | 35-450 | + | 26-350 |
. | . | 3-5 mo after CBT . | . | . | . | 12-15 mo after CBT . | . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | HCMV reactive . | HCMV . | . | CA . | . | HCMV . | . | CA . | . | ||||||
Patient no. . | . | Bulk PR . | LDA F . | Bulk PR . | LDA F . | Bulk PR . | LDA F . | Bulk PR . | LDA F . | ||||||
CBT-sib | |||||||||||||||
1 | Yes | + | ND | − | ND | + | ND | + | ND | ||||||
2 | Yes | + | ND | + | ND | + | ND | + | ND | ||||||
3 | No | ND | ND | − | ND | ND | ND | − | ND | ||||||
4 | No | ND | ND | + | ND | ND | ND | + | ND | ||||||
5 | No | ND | ND | + | ND | ND | ND | + | ND | ||||||
6 | No | + | 40 | + | 76 | + | 77 | + | 76 | ||||||
7 | No | + | 80 | − | 15 | + | 160 | + | 210 | ||||||
8 | No | + | 125 | + | 111 | + | 313 | + | 365 | ||||||
9 | No | + | 325 | − | 11 | + | 350 | + | 380 | ||||||
10 | No | + | 550 | − | 12 | + | 520 | + | 90 | ||||||
11 | No | − | 15 | + | 48 | − | 12 | − | 16 | ||||||
CBT-ud | |||||||||||||||
12 | No | − | ND | − | ND | + | ND | − | ND | ||||||
13 | No | ND | ND | + | ND | ND | ND | + | ND | ||||||
14 | Yes | + | 62 | − | 19 | + | 66 | + | 125 | ||||||
15 | No | − | − | − | − | − | − | − | − | ||||||
16 | Yes | − | 12 | − | 43 | − | 12 | − | 6 | ||||||
Control ranges | NA | + | 35-450 | + | 26-350 |
Control values were obtained from 12 age-matched healthy controls. A positive (+) PR is SI > 2 and net cpm > 3000; a negative PR (−) is SI < 2 and net cpm < 3000. PR indicates proliferative response; F, frequency (expressed as PTLp/106 input cells); and ND, not done.